The FDA says it plans to use artificial intelligence to help speed the approval of new drugs and medical devices.

Recursion Pharmaceuticals (NASDAQ: RXRX) is not the most famous artificial intelligence (AI) stock on the market, but the ...

Italy-based Bracco Imaging and Subtle Medical have obtained an EU CE mark for AiMIFY, a jointly developed software designed ...

BIO International Convention (BIO2025), the world’s largest annual biotech event, will take place from June 16 to 19 (U.S.

AstraZeneca, Pfizer and more are leveraging the computational power of AI to better design trials, predict the potential ...

Novartis AG (NYSE:NVS) is one of the 10 Undervalued European Stocks to Invest in Now. Deutsche Bank analyst Emmanuel ...

Ambient listening software is part of a buzzy new technology being marketed as AI “scribes,” or assistants, to help doctors ...

Elsa” is the FDA’s new anthropomorphized AI tool which, the FDA hopes, will speed up clearances, licenses, and approvals ...

The company announced that the US FDA has expanded the approved use of its oral antiviral drug Mavyret, developed in ...

The FDA plans to "unleash AI" on new drug evaluations in order to "radically increase efficiency in the review process." ...

This story is from the next print edition of MIT Technology Review, which explores power—who has it, and who wants it. It’s ...